504480 | Conantokin G - CAS 93438-65-4 - Calbiochem

504480
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₈₈H₁₃₉N₂₆O₄₄: GE(Gla)(Gla)LQ(Gla)NQ(Gla)LIR(Gla)KSN-NH₂ 93438-65-4

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      5.04480.0001
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 100 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewThe most selective and potent non-competitive antagonist among the members of the conantokin peptide family for NR2B-containing NMDAR channels (Ki = 0.8 µM with close to 100% inhibition of NR1/NR2B mediated current). Widely used for studies related to NMDAR neurotransmissions in both peripheral and center nervous systems.
          Catalogue Number504480
          Brand Family Calbiochem®
          SynonymsGly-Glu-γ-CarboxyGlu-γ-CarboxyGlu-Leu-Gln-γ-CarboxyGlu-Asn-Gln-γ-CarboxyGlu-Leu-Ile-Arg-γ-CarboxyGlu-Lys-Ser-Asn-NH2
          References
          ReferencesSheng, Z., et al. 2007. Neuropharmacology. 53, 145.
          Sheng, Z., et al. 2009. Neuropharmacology. 57, 127.
          Zhou, L., et al. 1996. J. Neurochemistry. 66, 620.
          Hammerland, L., et al. 1992. Eur. J. Pharmacol. 226, 239.
          Mena, E., et al. 1990. Neurosci Lett. 118, 241.
          Donevan, D., et al. 2000. Mol Pharmacol. 58, 614.
          Product Information
          CAS number93438-65-4
          FormWhite powder
          Hill FormulaC₈₈H₁₃₉N₂₆O₄₄: GE(Gla)(Gla)LQ(Gla)NQ(Gla)LIR(Gla)KSN-NH₂
          Chemical formulaC₈₈H₁₃₉N₂₆O₄₄: GE(Gla)(Gla)LQ(Gla)NQ(Gla)LIR(Gla)KSN-NH₂
          Sold on the basis of peptide contentY
          Applications
          Biological Information
          Primary TargetNMDA receptors
          Primary Target K<sub>i</sub>0.8 µM
          Purity≥95% by HPLC
          Physicochemical Information
          Peptide ContentY
          Peptide SequenceGly-Glu-γ-CarboxyGlu-γ-CarboxyGlu-Leu-Gln-γ-CarboxyGlu-Asn-Gln-γ-CarboxyGlu-Leu-Ile-Arg-γ-CarboxyGlu-Lys-Ser-Asn-NH₂
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          References

          Reference overview
          Sheng, Z., et al. 2007. Neuropharmacology. 53, 145.
          Sheng, Z., et al. 2009. Neuropharmacology. 57, 127.
          Zhou, L., et al. 1996. J. Neurochemistry. 66, 620.
          Hammerland, L., et al. 1992. Eur. J. Pharmacol. 226, 239.
          Mena, E., et al. 1990. Neurosci Lett. 118, 241.
          Donevan, D., et al. 2000. Mol Pharmacol. 58, 614.

          Brochure

          Title
          NPI Flyer- Epigenetics and Nuclear Function Feature (EMD)
          Neuroscience Solutions for productive research
          New Products - Antibodies, Small Molecule, Inhibitors
          Pathways and Biomarkers of Glutamatergic Synapse Flyer (EMD)

          Technical Info

          Title
          White Paper: Further considerations of antibody validation and usage. (EMD)
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision19-September-2014 JSW
          SynonymsGly-Glu-γ-CarboxyGlu-γ-CarboxyGlu-Leu-Gln-γ-CarboxyGlu-Asn-Gln-γ-CarboxyGlu-Leu-Ile-Arg-γ-CarboxyGlu-Lys-Ser-Asn-NH2
          DescriptionThe most selective and potent non-competitive antagonist among the members of the conantokin peptide family for NR2B-containing NMDAR channels (Ki = 0.8 µM with close to 100% inhibition of NR1/NR2B mediated current). Widely used for studies related to NMDAR neurotransmissions in both peripheral and center nervous systems.
          FormWhite powder
          CAS number93438-65-4
          Chemical formulaC₈₈H₁₃₉N₂₆O₄₄: GE(Gla)(Gla)LQ(Gla)NQ(Gla)LIR(Gla)KSN-NH₂
          Peptide SequenceGly-Glu-γ-CarboxyGlu-γ-CarboxyGlu-Leu-Gln-γ-CarboxyGlu-Asn-Gln-γ-CarboxyGlu-Leu-Ile-Arg-γ-CarboxyGlu-Lys-Ser-Asn-NH₂
          Purity≥95% by HPLC
          SolubilityH₂O (1 mg/ml)
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesSheng, Z., et al. 2007. Neuropharmacology. 53, 145.
          Sheng, Z., et al. 2009. Neuropharmacology. 57, 127.
          Zhou, L., et al. 1996. J. Neurochemistry. 66, 620.
          Hammerland, L., et al. 1992. Eur. J. Pharmacol. 226, 239.
          Mena, E., et al. 1990. Neurosci Lett. 118, 241.
          Donevan, D., et al. 2000. Mol Pharmacol. 58, 614.